Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY – Research Report), UnitedHealth (UNH – Research Report) and Caliber Imaging & Diagnostic (LCDX – Research Report).
Eli Lilly & Co (LLY)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $550.00. The company’s shares closed last Monday at $447.14, close to its 52-week high of $469.87.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $483.34, representing a 7.5% upside. In a report issued on July 14, HSBC also initiated coverage with a Buy rating on the stock with a $560.00 price target.
See today’s best-performing stocks on TipRanks >>
UnitedHealth (UNH)
Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on UnitedHealth yesterday and set a price target of $610.00. The company’s shares closed last Monday at $484.08.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of
UnitedHealth has an analyst consensus of Strong Buy, with a price target consensus of $569.94, implying a 18.5% upside from current levels. In a report issued on July 14, Bank of America Securities also maintained a Buy rating on the stock with a $650.00 price target.
Caliber Imaging & Diagnostic (LCDX)
In a report released yesterday, John Murphy from Bank of America Securities maintained a Hold rating on Caliber Imaging & Diagnostic, with a price target of $8.00.
According to TipRanks.com, Murphy is a 5-star analyst with an average return of
Currently, the analyst consensus on Caliber Imaging & Diagnostic is a Hold with an average price target of $8.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LLY:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Microsoft upgraded, AT&T downgraded: Wall Street’s top analyst calls
- Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
- Medicxi confirms Versanis to be acquired by Eli Lilly for up to $1.925B cash
- Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
